1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Protein Homeostasis
3.3. Post Translational Protein Modifications
3.4. Ubiquitin and the Ubiquitin Proteasome System (UPS)
3.4.1. Structure and Functions of Ubiquitin
3.4.2. Overview of the UPS
3.4.2.1. Components of the UPS
3.4.2.2. Ubiquitin-based Protein Degradation Pathway
3.5. Therapeutic Applications of the UPS
3.6. Ubiquitin Enzyme Inhibitors
3.6.1. Advantages and Challenges
3.7. Overview of Targeted Protein Degradation
3.7.1. Historical Development of Protein Degraders
3.7.2. Types of Protein Degraders
3.7.2.1. Proteolysis Targeting Chimeras (PROTACs)
3.7.2.2. Other Chimeric Protein Targeting Molecules
3.7.2.2.1. Endosome Targeting Chimeras (ENDTACs)
3.7.2.2.2. Lysosome Targeting Chimeras (LYTACs)
3.7.2.2.3. Photochemically Targeted Chimeras (PHOTACs)
3.7.2.3. Epichaperome Inhibitors
3.7.2.4. Hydrophobic Tags
3.7.2.5. Immuno-modulatory Imide Drugs (IMiDs)
3.7.2.6. Molecular Glues
3.7.2.7. Protein Homeostatic Modulators
3.7.2.8. Selective Hormone Receptor Degraders (SHRDs)
3.7.2.9. Specific and Non-genetic IAP-dependent Protein Erasers (SNIPERs)
3.7.2.10. Specific Bromodomain and Extra-terminal Motif (BET) Inhibitors and Deubiquitinase (DUB) Inhibitors
3.8. Market Growth Drivers and Roadblocks
3.9. Recent Developments and Upcoming Trends

4. CURRENT MARKET LANDSCAPE: TARGET PROTEIN DEGRADATION-BASED THERAPEUTICS
4.1. Chapter Overview
4.2. Targeted Protein Degradation-based Therapeutics: Development Pipeline
4.2.1. Analysis by Type of Protein Degrader
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Target Indication
4.2.5. Analysis by Biological Target
4.2.6. Analysis by Associated Ubiquitin Ligase
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Route of Administration
4.3. Targeted Protein Degradation-based Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Protein Degrader
4.3.4. Analysis by Location of Headquarters
4.3.5. Leading Players: Analysis by Number of Drug Candidates

5. CURRENT MARKET LANDSCAPE: TARGET PROTEIN DEGRADATION ENABLING TECHNOLOGIES
5.1. Chapter Overview
5.2. Targeted Protein Degradation Enabling Technologies: List of Research Tools / Key Technology Platforms
5.2.1. Analysis by Type of Protein Degrader
5.2.2. Analysis by Number of Drugs under Development
5.3. Targeted Protein Degradation Enabling Technologies: Developer Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Developers with Late-stage Clinical Candidates
6.2.1. Radius Health
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Targeted Protein Degradation-based Product Portfolio
6.2.1.3.1. Elacestrant (RAD1901)
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Celgene
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Targeted Protein Degradation-based Drug Portfolio
6.2.2.3.1. Avadomide (CC-122)
6.2.2.3.2. Iberdomide (CC-220)
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Sanofi Genzyme
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Targeted Protein Degradation-based Drug Portfolio
6.2.3.3.1. SAR439869
6.2.3.4. Recent Developments and Future Outlook
6.2.4. AstraZeneca
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Targeted Protein Degradation-based Drug Portfolio
6.2.4.3.1. AZD9833
6.2.4.4. Recent Developments and Future Outlook
6.3. Developers with Preclinical / Early-stage Clinical Candidates
6.3.1. Arvinas
6.3.2. BioTheryX
6.3.3. Captor Therapeutics
6.3.4. C4 Therapeutics
6.3.5. Genentech
6.3.6. Hinova Pharmaceuticals
6.3.7. Kangpu Biopharmaceuticals
6.3.8. Kymera Therapeutics
6.3.9. Mission Therapeutics
6.3.10. Progenra
6.3.11. Zenopharm

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Clinical Trials
7.3.1. Analysis by Trial Registration Year
7.3.2. Geographical Analysis by Number of Clinical Trials
7.3.3. Geographical Analysis by Enrolled Patient Population
7.3.4. Analysis by Type of Protein Degrader
7.3.5. Analysis by Trial Phase
7.3.6. Analysis by Study Design
7.3.7. Analysis by Type of Sponsor / Collaborator
7.3.8. Most Active Players: Analysis by Number of Registered Trials
7.3.9. Analysis by Trial Focus
7.3.10. Analysis by Therapeutic Area
7.3.11. Analysis by Clinical Endpoints

8. ACADEMIC GRANTS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Target Protein Degradation: Analysis of Academic Grants
8.3.1. Analysis by Year of Grant Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Funding Institute Center
8.3.4. Analysis by Support Period
8.3.5. Analysis by Funding Institute Center and Support Period
8.3.6. Analysis by Type of Grant Application
8.3.7. Analysis by Purpose of Grant Award
8.3.8. Analysis by Activity Code
8.3.9. Emerging Focus Areas (Word Cloud)
8.3.10. Analysis by Study Section Involved
8.3.11. Popular NIH Departments: Analysis by Number of Grants
8.3.12. Analysis by Type of Recipient Organization
8.3.13. Prominent Program Officers: Analysis by Number of Grants
8.3.14. Popular Recipient Organizations: Analysis by Number of Grants
8.3.15. Regional Distribution of Recipient Organizations

9. PUBLICATION ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Targeted Protein Degradation-Based Therapeutics and Technologies: Recent Publications
9.3.1. Analysis by Year of Publication
9.3.2. Analysis by Study Objective
9.3.3. Emerging Focus Areas
9.3.4. Analysis by Type of Protein Degrader
9.3.5. Analysis by Target Protein
9.3.6. Analysis by Target Enzyme
9.3.7. Analysis by Target Indication
9.3.8. Analysis by Type of Publisher
9.3.9. Leading Players: Analysis by Number of Publications
9.3.10. Leading Players: Geographical Analysis by Number of Publications
9.3.11. Key Journals: Analysis by Number of Publications

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Targeted Protein Degradation Technologies: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Application Year
10.3.3. Analysis by Geographical Location
10.3.4. Analysis by CPC Symbols
10.3.5. Emerging Focus Areas (Word Cloud)
10.3.6. Analysis by Type of Organization
10.3.7. Leading Players: Analysis by Number of Patents
10.4. Target Protein Degradation Technologies: Benchmarking Patent Analysis
10.4.1. Analysis by Patent Characteristics
10.5. Target Protein Degradation-based Technologies: Patent Valuation Analysis
10.6. Leading Patents by Number of Citations

11. KOL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Principal Investigators
11.3.1. Analysis by Designation
11.3.2. Analysis by Phase of Development and Type of Protein Degrader
11.3.3. Analysis by Therapeutic Area
11.3.4. Analysis by Type of Organization
11.3.5. Analysis by Location of Organization
11.3.6. Leading Organizations: Analysis by Number of Affiliated Principal Investigators
11.4. Prominent Key Opinion Leaders (KOLs)
11.5. KOL Benchmarking: Roots Analysis versus Third Party Scoring (ResearchGate Score)
11.6. Profiles of Most Active KOLs
11.6.1. Profile: KOL A (Barbara Ann Karmanos Cancer Center)
11.6.2. Profile: KOL B (Celgene)
11.6.3. Profile: KOL C (Feinberg School of Medicine, Northwestern University)
11.6.4. Profile: KOL D (Royal Marsden NHS Foundation Trust)
11.6.5. Profile: KOL E (Samus Therapeutics)
11.6.6. Profile: KOL F (Stanford Women Cancer Center)
11.6.7. Profile: KOL G (University of North Carolina at Chapel Hill)
11.6.8. Profile: KOL H (University of Toledo)

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Targeted Protein Degradation-based Therapeutics and Technologies: Recent Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Type of Protein Degrader
12.3.4. Analysis by Protein Degradation Technology
12.3.5. Analysis by Therapeutic Area
12.3.6. Most Active Players: Analysis by Number of Partnerships
12.3.7. Geographical Analysis
12.3.7.1. Most Active Players: Regional Analysis by Number of Partnerships
12.3.7.2. Intercontinental and Intracontinental Agreements

13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. Targeted Protein Degradation-based Therapeutics and Technologies: Recent Funding Instances
13.3.1. Analysis by Year of Investment
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Analysis by Amount Invested for Different Types of Degraders
13.3.5. Analysis by Amount Invested across Different Therapeutic Areas
13.3.6. Analysis by Amount Invested across Different Technology Platforms
13.3.7. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
13.3.8. Most Active Investors: Analysis by Participation
13.3.9. Geographical Analysis by Amount Invested
13.4. Concluding Remarks

14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Targeted Protein Degradation-based Therapeutics and Technologies: Information on Licensing Deals
14.4. Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, 2021-2030
14.4.1. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader
14.4.1.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, 2021-2030
14.4.1.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, 2021-2030
14.4.1.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs / SERDs, 2021-2030
14.4.1.4. Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, 2021-2030
14.4.1.5. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Inhibitors, 2021-2030
14.4.2. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area
14.4.2.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, 2021-2030
14.4.2.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, 2021-2030
14.4.2.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, 2021-2030
14.4.3. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration
14.4.3.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, 2021-2030
14.4.3.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, 2021-2030
14.4.3.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes of Administration, 2021-2030
14.4.4. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Geography
14.4.4.1. Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, 2021-2030
14.4.4.2. Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, 2021-2030
14.4.4.3. Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, 2021-2030
14.4.5. Targeted Protein Degradation-based Therapeutics and Technologies Market: Share of Key Contributing Technologies, 2021-2030

15. LICENSING DEAL STRUCTURE

16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Polyprox Therapeutics
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Laura Itzhaki, Founder and Chief Scientific Officer
16.3. Xios Therapeutics
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Louise Bergeron, Vice President
16.4. Almac
16.4.1. Company Snapshot
16.4.2. Interview Transcript: Martin Wiles, Vice President Business Development and Licensing & Gerald Gavory, Director of Biology
16.5. Ubiquigent
16.5.1. Company Snapshot
16.5.2. Interview Transcript: Jason Brown, Scientific and Business Development Director
16.6. Interview Transcript: Anonymous, Director of Oncology Research
16.7. Interview Transcript: Anonymous, Chief Scientific Officer
16.8. Mission Therapeutics
16.8.1. Company Snapshot
16.8.2. Paul Wallace, Chief Business Officer
16.9. Francis Crick Institute
16.9.1. Company Snapshot
16.9.2. Interview Transcript: Katrin Rittinger, Research Group Leader
16.10. University of Delaware
16.10.1. Company Snapshot
16.10.2. Interview Transcript: Zhihao Zhuang, Associate Professor, Department of Chemistry and Biochemistry

17. CONCLUDING REMARKS

18. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures
Figure 3.1 Important Mechanisms of Protein Surveillance
Figure 3.2 Common Types of Post-translational Modifications
Figure 3.3 Mechanism-based Analogies in Phosphorylation and Ubiquitination
Figure 3.4 Key Differences between Phosphorylation and Ubiquitination
Figure 3.5 Ubiquitin: Types of Target Proteins
Figure 3.6 Genetic Evolution of the UPS in Eukaryotes
Figure 3.7 Key Components of the UPS
Figure 3.8 Key Steps Involved in Protein Degradation via the Ubiquitin-Proteasome Pathway
Figure 3.9 Different Modes of Ubiquitination
Figure 3.10 Biological Functions of Ubiquitination
Figure 3.11 Role of UPS in Disease Development Process
Figure 3.12 Key Therapeutic Areas Targeted by UPS Modulating Drug Candidates
Figure 3.13 Key Differences Between Protein Degrader and Protein Inhibitor
Figure 3.14 Historical Evolution of Targeted Protein Degradation
Figure 3.15 Types of Protein Degraders
Figure 3.16 Mechanism of Action of PROTACs
Figure 3.17 Mechanism of Action of ENDTACs
Figure 3.18 Mechanism of Action of LYTACs
Figure 3.19 Mechanism of Action of PHOTACs
Figure 3.20 Mechanism of Action of Epichaperome Inhibitors
Figure 3.21 Mechanism of Action of Hydrophobic Tags
Figure 3.22 Mechanism of Action of IMiDs
Figure 3.23 Mechanism of Action of Molecular Glues
Figure 3.24 Mechanism of Action of Protein Homeostatic Modulators
Figure 3.25 Mechanism of Action of SHRDs
Figure 3.26 Mechanism of Action of SNIPERs
Figure 3.27 Key Growth Drivers and Roadblocks Related to Targeted Protein Degraders
Figure 4.1 Targeted Protein Degradation-based Therapeutics: Distribution by Type of Protein Degrader
Figure 4.2 Targeted Protein Degradation-based Therapeutics: Distribution by Phase of Development
Figure 4.3 Targeted Protein Degradation-based Therapeutics: Distribution by Phase of Development and Type of Protein Degrader
Figure 4.4 Targeted Protein Degradation-based Therapeutics: Distribution by Therapeutic Area
Figure 4.5 Popular Indications: Distribution by Number of Drug Candidates
Figure 4.6 Targeted Protein Degradation-based Therapeutics: Distribution by Therapeutic Area and Type of Protein Degrader
Figure 4.7 Targeted Protein Degradation-based Therapeutics: Distribution by Therapeutic Area and Phase of Development
Figure 4.8 Popular Biological Target: Distribution by Number of Drug Candidates
Figure 4.9 Popular Associated Ubiquitin Ligase: Distribution by Number of Drug Candidates
Figure 4.10 Targeted Protein Degradation-based Therapeutics: Distribution by Biological Target and Type of Protein Degrader
Figure 4.11 Targeted Protein Degradation-based Therapeutics: Distribution by Biological Target and Phase of Development
Figure 4.12 Targeted Protein Degradation-based Therapeutics: Distribution by Type of Therapy
Figure 4.13 Targeted Protein Degradation-based Therapeutics: Distribution by Route of Administration
Figure 4.14 Targeted Protein Degradation-based Therapeutics: Distribution of Industry Players by Year of Establishment
Figure 4.15 Targeted Protein Degradation-based Therapeutics: Distribution of Industry Players by Location of Headquarters
Figure 4.16 Targeted Protein Degradation-based Therapeutics: Distribution of Industry Players by Company Size
Figure 4.17 Targeted Protein Degradation-based Therapeutics: Distribution of Industry Players by Type of Protein Degrader
Figure 4.18 Targeted Protein Degradation-based Therapeutics: Geographical Distribution of Industry Players by Type of Protein Degrader
Figure 4.19 Leading Players: Distribution by Number of Drug Candidates
Figure 5.1 Targeted Protein Degradation Enabling Technologies: Distribution by Type of Protein Degrader
Figure 5.2 Targeted Protein Degradation Enabling Technologies: Distribution by Number of Drugs Under Development
Figure 5.3 Targeted Protein Degradation Enabling Technologies: Distribution of Industry Players by Year of Establishment
Figure 5.4 Targeted Protein Degradation Enabling Technologies: Distribution of Industry Players by Location of Headquarters
Figure 5.5 Targeted Protein Degradation Enabling Technologies: Distribution of Industry Players by Company Size
Figure 6.1 Celgene: Net Revenues, FY 2014 - Q3 2019 (USD Million)
Figure 6.2 Sanofi Genzyme: Net Revenues, FY 2014 - H1 2020 (USD Million)
Figure 6.3 AstraZeneca: Net Revenues, FY 2014 - Q3 2020 (USD Billion)
Figure 7.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.2 Clinical Trials: Cumulative Distribution by Trial Registration Year, Pre-2012-2021 (till January)
Figure 7.3 Clinical Trial Analysis: Geographical Distribution of Trials
Figure 7.4 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
Figure 7.5 Clinical Trial Analysis: Distribution by Type of Protein Degrader
Figure 7.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.7 Clinical Trial Analysis: Distribution by Type of Protein Degrader and Trial Phase
Figure 7.8 Clinical Trial Analysis: Distribution by Registration Year, Type of Protein Degrader and Leading Players
Figure 7.9 Clinical Trial Analysis: Distribution by Target Indication, Type of Protein Degrader, Trial Phase and Trial Registration Year
Figure 7.10 Clinical Trial Analysis: Distribution by Study Design
Figure 7.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.12 Most Active Players: Distribution by Number of Registered Trials
Figure 7.13 Word Cloud: Popular Keywords
Figure 7.14 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 7.15 Clinical Trial Analysis: Benchmarking by Number of Trials across Popular Indications
Figure 7.16 Clinical Trial Analysis: Distribution by Trial Phase and Popular Indications
Figure 7.17 Clinical Trial Analysis: Benchmarking of Leading Players by Number of Trials across Key Therapeutic Indications
Figure 7.18 Clinical Trials: Most Popular Clinical Endpoints by Phase of Development
Figure 8.1 Grant Analysis: Cumulative Trend by Year of Grant Award, 2016-2020
Figure 8.2 Grant Analysis: Year-wise Distribution of Grant Amount (USD Million), 2016-2020
Figure 8.3 Grant Analysis: Distribution by Funding Institute Center
Figure 8.4 Grant Analysis: Distribution by Support Period
Figure 8.5 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 8.6 Grant Analysis: Distribution by Type of Grant Application
Figure 8.7 Grant Analysis: Distribution by Purpose of Grant Award
Figure 8.8 Grant Analysis: Distribution by Activity Code
Figure 8.9 Word Cloud: Emerging Focus Areas
Figure 8.10 Grant Analysis: Distribution by Study Section Involved
Figure 8.11 Popular NIH Departments: Distribution by Number of Grants
Figure 8.12 Grant Analysis: Distribution by Type of Recipient Organization
Figure 8.13 Prominent Program Officers: Distribution by Number of Grants
Figure 8.14 Popular Recipient Organizations: Distribution by Number of Grants
Figure 8.15 Grant Analysis: Regional Distribution of Recipient Organizations
Figure 9.1 Recent Publications: Distribution by Type of Publication
Figure 9.2 Recent Publications: Cumulative Year-wise Trend, 2017-Q3 2019
Figure 9.3 Recent Publications: Distribution by Study Objective
Figure 9.4 Recent Publications: Emerging Focus Areas
Figure 9.5 Recent Publications: Distribution by Type of Protein Degrader
Figure 9.6 Recent Publications: Distribution by Target Protein
Figure 9.7 Recent Publications: Distribution by Target Enzyme
Figure 9.8 Popular Target Indications: Distribution by Number of Publications
Figure 9.9 Recent Publications: Distribution by Type of Publisher
Figure 9.10 Most Active Players: Distribution by Number of Publications
Figure 9.11 Leading Players: Geographical Distribution by Number of Publications
Figure 9.12 Key Journals: Distribution by Number of Publications
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Cumulative Distribution by Publication Year, 2018-2020
Figure 10.3 Patent Analysis: Distribution by Application Year, Pre-2017-2020
Figure 10.4 Patent Analysis: Distribution by Geographical Location
Figure 10.5 Patent Analysis: Distribution by CPC Symbols
Figure 10.6 Patent Analysis: Emerging Focus Areas
Figure 10.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Figure 10.8 Patent Analysis: Leading Industry Players
Figure 10.9 Patent Analysis: Leading Non-Industry Players
Figure 10.10 Patent Analysis: Leading Individual Assignees
Figure 10.11 Patent Analysis (Leading Industry Players): Benchmarking by Patent Characteristics (CPC Symbols)
Figure 10.12 Patent Analysis: Distribution of Patents by Age (2001-2020)
Figure 10.13 Targeted Protein Degradation Technologies: Patent Valuation
Figure 11.1 KOLs: Geographical Distribution of Principal Investigators
Figure 11.2 KOLs: Distribution by Designation
Figure 11.3 KOLs: Distribution by Phase of Development and Type of Protein Degrader
Figure 11.4 KOLs: Distribution by Therapeutic Area
Figure 11.5 KOLs: Distribution by Type of Organization
Figure 11.6 KOLs: Distribution by Location of Organization
Figure 11.7 Leading Organizations: Distribution by Number of Affiliated Principal Investigators
Figure 11.8 KOLs: Dot-Plot of Principal Investigators
Figure 11.9 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Figure 11.10 Most Prominent KOLs
Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2021 (till January)
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 12.4 Partnerships and Collaborations: Distribution by Type of Protein Degrader
Figure 12.5 Partnerships and Collaborations: Year-wise Trend by Type of Protein Degrader
Figure 12.6 Partnerships and Collaborations: Distribution by Type of Protein Degrader and Type of Partnership
Figure 12.7 Popular Technology Platforms: Distribution by Number of Partnerships
Figure 12.8 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 12.9 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Figure 12.10 Partnerships and Collaborations: Distribution by Protein Degradation Technology
Figure 12.11 Most Active Players: Distribution by Number of Partnerships
Figure 12.12 Most Active Players: Geographical Distribution by Number of Partnerships
Figure 12.13 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 13.1 Funding and Investments: Distribution of Number of Funding Instances by Year of Establishment and Type of Funding, 2014-2020
Figure 13.2 Funding and Investments: Cumulative Year-wise Trend, 2014-2020
Figure 13.3 Funding and Investments: Cumulative Amount Invested by Year, 2014-2020 (USD Million)
Figure 13.4 Funding and Investments: Distribution by Type of Funding
Figure 13.5 Funding and Investments: Distribution by Amount Invested (USD Million) and Type of Funding
Figure 13.6 Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding
Figure 13.7 Funding and Investments: Summary of Investments, 2014-2020 (USD Million)
Figure 13.8 Protein Degraders: Distribution by Number of Funding Instances
Figure 13.9 Protein Degraders: Distribution by Amount Invested (USD Million)
Figure 13.10 Funding and Investments: Year-wise Distribution of Amount Invested for Different Protein Degraders, 2014-2020 (USD Million)
Figure 13.11 Popular Therapeutic Areas: Distribution by Number of Funding Instances
Figure 13.12 Popular Therapeutic Areas: Distribution by Number of Funding Instances across Different Protein Degraders
Figure 13.13 Popular Therapeutic Areas: Distribution by Amount Invested (USD Million)
Figure 13.14 Popular Technology Platforms: Distribution by Amount Invested (USD Million)
Figure 13.15 Most Active Players: Distribution by Number of Funding Instances
Figure 13.16 Most Active Players: Distribution by Capital Amount Raised (USD Million)
Figure 13.17 Most Active Investors: Distribution by Number of Funding Instances
Figure 13.18 Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Figure 13.19 Funding and Investment Summary
Figure 14.1 Licensing Agreements: Distribution of Financial Components
Figure 14.2 Targeted Protein Degradation-based Therapeutics and Technologies: Information on Licensing Deals
Figure 14.3 Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, 2021-2030 (USD Million)
Figure 14.4 Targeted Protein Degradation-based Therapeutics and Technologies Market by Upfront Payments, till 2030 (USD Million)
Figure 14.5 Targeted Protein Degradation-based Therapeutics and Technologies Market by Milestone Payments, till 2030 (USD Million)
Figure 14.6 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader, 2021 and 2030
Figure 14.7 Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, 2021-2030 (USD Million)
Figure 14.8 Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, 2021-2030 (USD Million)
Figure 14.9 Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs / SERDs, 2021-2030 (USD Million)
Figure 14.10 Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, 2021-2030 (USD Million)
Figure 14.11 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area, 2021 and 2030
Figure 14.12 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, 2021-2030 (USD Million)
Figure 14.13 Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, 2021-2030 (USD Million)
Figure 14.14 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, 2021-2030 (USD Million)
Figure 14.15 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration, 2021 and 2030
Figure 14.16 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, 2021-2030 (USD Million)
Figure 14.17 Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, 2021-2030 (USD Million)
Figure 14.18 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes of Administration, 2021-2030 (USD Million)
Figure 14.19 Targeted Protein Degradation-based Therapeutics and Technologies Market: Regional Distribution, 2021 and 2030
Figure 14.20 Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, 2021-2030 (USD Million)
Figure 14.21 Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, 2021-2030 (USD Million)
Figure 14.22 Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.23 Targeted Protein Degradation-based Therapeutics and Technologies Market for Key Contributing Technologies, 2021-2030 (USD Million)
Figure 17.1 Concluding Remarks: Current Market Landscape
Figure 17.2 Concluding Remarks: Clinical Trial Analysis
Figure 17.3 Concluding Remarks: Academic Grant Analysis
Figure 17.4 Concluding Remarks: Publication Analysis
Figure 17.5 Concluding Remarks: Patent Analysis
Figure 17.6 Concluding Remarks: Partnerships and Collaborations
Figure 17.7 Concluding Remarks: Funding Analysis
Figure 17.8 Concluding Remarks: Market Sizing and Opportunity AnalysisFigure 11.9 Vaccine CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
Figure 11.10 Vaccine CMOs: Distribution by Type of Services Offered
Figure 11.11 Vaccine CMOs: Distribution by Expression System Used
Figure 11.12 Vaccine CMOs: Distribution by Type of Vaccine Manufactured
Figure 11.13 Vaccine CMOs: Distribution by Type of Vaccine Manufactured and Location of Headquarters

List of Tables
Table 3.1 Structural Classification of Ubiquitin
Table 4.1 Targeted Protein Degradation-based Therapeutics: Development Pipeline
Table 4.2 Targeted Protein Degradation-based Therapeutics: Information on Therapeutic Area and Phase of Development
Table 4.3 Targeted Protein Degradation-based Therapeutics: Information on Type of Protein Degrader
Table 4.3 Targeted Protein Degradation-based Therapeutics: Information on Target Enzyme, Target Protein, Signaling Pathway, Type of Therapy and Route of Administration
Table 4.4 Targeted Protein Degradation-based Therapeutics: Information on Marketed First Generation Protein Degraders
Table 4.5 Targeted Protein Degradation-based Therapeutics: Developer Landscape
Table 5.1 Targeted Protein Degradation Enabling Technologies: Information on Research Tools / Key Technology Platforms
Table 5.2 Targeted Protein Degradation Enabling Technologies: Developer Landscape
Table 6.1 Radius Health: Key Highlights
Table 6.2 Drug Profile: Elacestrant (RAD1901)
Table 6.3 Radius Health: Recent Developments and Future Outlook
Table 6.4 Celgene: Key Highlights
Table 6.5 Drug Profile: Avadomide (CC-122)
Table 6.6 Drug Profile: Iberdomide (CC-220)
Table 6.7 Celgene: Recent Developments and Future Outlook
Table 6.8 Sanofi Genzyme: Key Highlights
Table 6.9 Drug profile: SAR439869
Table 6.10 Sanofi Genzyme: Recent Developments and Future Outlook
Table 6.11 AstraZeneca: Key Highlights
Table 6.12 Drug profile: AZD9833
Table 6.13 AstraZeneca: Recent Developments and Future Outlook
Table 6.14 Arvinas: Key Highlights
Table 6.15 BioTheryX: Key Highlights
Table 6.16 Captor Therapeutics: Key Highlights
Table 6.17 C4 Therapeutics: Key Highlights
Table 6.18 Genentech: Key Highlights
Table 6.19 Hinova Pharmaceuticals: Key Highlights
Table 6.20 Kangpu Biopharmaceuticals: Key Highlights
Table 6.21 Kymera Therapeutics: Key Highlights
Table 6.22 Mission Therapeutics: Key Highlights
Table 6.23 Progenra: Key Highlights
Table 6.24 Zenopharm: Key Highlights
Table 9.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Recent Publications, 2017 - Q3 2019
Table 11.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Principal Investigators
Table 11.2 KOLs: Roots Analysis Proprietary Scoring System
Table 11.3 Profile: KOL A (Barbara Ann Karmanos Cancer Center)
Table 11.4 Profile: KOL B (Celgene)
Table 11.5 Profile: KOL C (Feinberg School of Medicine, Northwestern University)
Table 11.6 Profile: KOL D (Royal Marsden NHS Foundation Trust)
Table 11.7 Profile: KOL E (Samus Therapeutics)
Table 11.8 Profile: KOL F (Stanford Women Cancer Center)
Table 11.9 Profile: KOL G (University of North Carolina at Chapel Hill)
Table 11.10 Profile: KOL H (University of Toledo)
Table 12.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Partnerships, 2014-2021 (till January)
Table 13.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Funding Instances, 2014-2020
Table 13.2 Targeted Protein Degradation-based Therapeutics and Technologies: Summary of Investments
Table 16.1 Polyprox Therapeutics: Company Snapshot
Table 16.2 Xios Therapeutics: Company Snapshot
Table 16.3 Almac: Company Snapshot
Table 16.4 Ubiquigent: Company Snapshot
Table 16.5 Mission Therapeutics: Company Snapshot

Please contact our Customer Support Center to get the complete Table of Contents